Loading…
← CockpitCompetitor Analysis › 300878.SZ Zhejiang Wecome Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Wecome Pharmaceutical Co., Ltd. Class A300878.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 72
Mkt cap
$632M
US dollars, full cap
$/day
$11.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-12.4 pp
WACC 7.7%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥29.85
1D-2.4%
1W-13.3%
1M+4.7%
3M-16.1%
6M-17.5%
YTD+17.0%
1Y+13.9%
ATR %6.1%
52w lowhigh25.8% off high

What Zhejiang Wecome Pharmaceutical does

Employees: 535

Zhejiang Wecome Pharmaceutical at a glance

Size Zhejiang Wecome Pharmaceutical (300878.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $632M, the 3127th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥29.85 on 18 Nov 2026.

Performance Over six months the shares fell 17.5%, against -19.0% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue grew 91.5% over the last twelve months (peer median +8.3%); the operating margin is -40.7% (peer median 9.2%).

Valuation It trades at 16.9× enterprise value to sales against a peer median of 3.0× (2nd most expensive of 17).

Capital Return on invested capital runs 12.4 points below its cost of capital (7.7% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026300878.SZ 87Peer median 81
Six months, rebased to 100: Zhejiang Wecome Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Wecome Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥252MCN¥225MCN¥349MCN¥518MCN¥531M
Revenue growth—-36%-33%-2%—
Gross profitCN¥144MCN¥48.2MCN¥96.4MCN¥239MCN¥293M
EBITDAn/a-CN¥61.4M-CN¥94.8MCN¥29.4MCN¥79.7M
Net income-CN¥127M-CN¥227M-CN¥147M-CN¥8.95MCN¥48.8M
Free cash flow-CN¥57.8M-CN¥81,740-CN¥147M-CN¥81.0M-CN¥28.2M
Capital expenditureCN¥49.4MCN¥67.2MCN¥127MCN¥139MCN¥173M
Total debtCN¥234MCN¥171MCN¥293MCN¥453MCN¥330M

Quarterly statements and history in the cockpit →

Zhejiang Wecome Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-40%-20%0%ABUS4123BCAX300016000566301211OLMAINNOVACAP4105ORCHPHARMA002940FDC603567SPARCDBV300233300878.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Wecome Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%+3,000%0×10×20×ABUS4123300016000566301211INNOVACAPORCHPHARMA300194603567185750SPARC300878.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Wecome Pharmaceutical is the large dot.

Zhejiang Wecome Pharmaceutical competitors and peer comparison

How Zhejiang Wecome Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Wecome Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300878.SZPeer medianRank in peer set
1-month return+4.7%-10.2%4th highest of 20
6-month return-17.5%-19.0%9th highest of 20
Distance from 52-week high-25.8%-38.0%6th highest of 20
Revenue growth (TTM)+91.5%+8.3%3rd highest of 17
Operating margin-40.7%9.2%2nd lowest of 16
EV / Sales16.9×3.0×2nd most expensive of 17
ROIC minus cost of capital-12.4 pp-3.4 pp2nd lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%3.4×27.1%+31.4%
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
FDC FDC.NSIndia$653M+3%+10%14%2.4×25.2%+10.3%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%2.5×n/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%

Questions

Which companies are Zhejiang Wecome Pharmaceutical's closest peers?
The cockpit's peer set: Arbutus Biopharma (ABUS), Center Laboratories (4123.TWO), Bicara Therapeutics (BCAX), Beijing Beilu Pharmaceutical (300016.SZ), Hainan Haiyao (000566.SZ), Hubei Biocause Heilen Pharmaceutical (301211.SZ), Olema Pharmaceuticals (OLMA), Innova Captab (INNOVACAP.NS).
Is Zhejiang Wecome Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 16.9× against a peer median of 3.0×, 2nd most expensive of 17 in its peer set.
How has Zhejiang Wecome Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -17.5% against -19.0% for the median peer; over one year +13.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.